Hikma has struck a deal with Glenmark to gain US rights to the Indian firm’s investigational Ryaltris (olopatadine/mometasone) nasal spray. The agreement builds on what Hikma said was its “market-leading position in nasal allergy sprays.”
Glenmark will continue to develop the product and will be responsible for gaining US Food and Drug Administration approval, while Hikma will market Ryaltris and will also be able to produce the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?